Nkarta to Participate at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at two upcoming investor conferences:

22nd Annual Needham Virtual Healthcare ConferenceApril 17, 20233:00 p.m. ET – fireside chat

Canaccord Genuity Horizons in Oncology Virtual ConferenceApril 20, 20233:00 p.m. ET – panel discussion

A simultaneous webcast of each event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.

About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for patients with cancer. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep anti-tumor activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.

Nkarta Media/Investor Contact:Greg MannNkarta, Inc.[email protected]

You May Also Be Interested In

• Solésence Reports Second Quarter 2026 Financial Results
• QNB Corp. Announces Launch of Common Stock Offering
• Rocket Alumni Solutions Launches Easy Submit for Content Updates by Email or Text